Voclosporin, the first FDA-approved oral therapy for lupus nephritis, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.
The FDA late Friday approved voclosporin for the treatment of lupus nephritis (LN), a condition that is associated with kidney damage, kidney failure, cardiac events, and death.
Voclosporin, the first FDA-approved oral therapy for LN, will be sold as Lupkynis by Aurinia Pharmaceuticals and is approved for use in conjunction with immunosuppressive treatment.
The approval is the second for an LN therapy recently; the FDA expanded the indication for belimumab to adults with LN last month. Belimumab was first approved in 2011 for systemic lupus erythematosus (SLE). LN affects about 40% to 50% of patients with SLE, which disproportionately affects Black, Hispanic, and Asian individuals; most patients are female.
Lupus is a classic autoimmune disease and arrives suddenly in people with a genetic predisposition. For the most part, clinicians use immunosuppressive drugs that limit immune system activity, including hydroxychloroquine—which experienced shortages last year when it was promoted as a possible treatment for coronavirus disease 2019, despite a lack of evidence.
The development of voclosporin stemmed from the AURORA phase 3 study and the AURA-LV phase 2 study. Over the course of 52 weeks, patients receiving voclosporin had vastly improved outcomes when taken in combination with standard-of-care therapy (SOC), mycophenolate mofetil (MMF), and low-dose steroids.
For both phase 2 and 3 studies, 533 patients with LN were given voclosporin 23.7 mg or a placebo twice a day in conjunction with SOC and a MMF target dose of 2 g daily. For the first 2 days, patients received intravenous (IV) methylprednisolone (up to 1 g), with a taper of oral corticosteroids after that. Oral prednisone dosage was 20 mg/day for patients weighing less than 45 kg and 25 mg/day for patients weighing at least 45 kg. By week 16, their target goal was a dose of 2.5 mg/day. Patients (with LN class III, IV, or V) were required to have baseline eGFR greater than 45 mL/min/1.73 m2.
The phase 3 study showed that voclosporin was twice as effective at achieving a complete renal response compared with SOC. Patients also obtained a 50% reduction in urine protein creatinine ratio twice as fast as those in the SOC group; in addition, a higher number of patients in the voclosporin group achieved a complete renal response by 24 weeks when compared with those in the SOC group.
Common adverse effects (>3%) included a decrease in glomerular filtration rate, hypertension, diarrhea, headache, anemia, cough, urinary tract infection, abdominal pain, dyspepsia, alopecia, renal impairment, mouth ulceration, fatigue, tremor, acute kidney injury, and decreased appetite.
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More